AstraZeneca Reports Positive Clinical Trial Results for New Drug

AstraZeneca announced positive results from a 52-week clinical trial for its therapeutic candidate, which achieved statistically significant complete endoscopic remission compared to a placebo. The trial indicated a notable reduction in inflammation and fibrosis in patients receiving the treatment. This advancement represents a significant milestone in AstraZeneca's clinical pipeline for the targeted condition.